Corporate America is on edge and hiring armed guards after the NYC office shooting
A deadly shooting at a New York City office tower on Monday has companies and executives boosting security across Wall Street and corporate America. Firms are scrambling to hire armed guards, conduct risk assessments, review security protocols, and reassure employees that they're safe, security experts said on Tuesday.
"The phone hasn't stopped since this morning," Sean Crowley, the cofounder and CEO of CTS Research and Investigations, told Business Insider. CTS, based in NYC, is a partner and co-owner of Illuno, an app — "Like Uber for hiring security guards," Crowley calls it — that makes it easy to hire law enforcement for security jobs.
Most of the calls, Crowley said, are coming from commercial and office property managers in Manhattan and downtown Brooklyn who want to bring in armed security guards, clad in suits and ties, to post in their lobbies. "This will more than double our workload," said Crowley, a former NYPD captain and commander of the Manhattan District Attorney's Office detective squad.
Corporate leaders are on edge after the second deadly shooting involving business executives in six months. Monday's attack, which played out at the New York City headquarters of the private equity firm Blackstone, left five dead, including real estate executive Wesley LePatner and the gunman. Monday's shooting followed the assassination of UnitedHealthcare CEO Brian Thompson in December. Companies are now rushing to reassure staff and bolster security as haunting images—like barricaded office doors—underscore growing fears that working for corporate America is no longer safe.
Don Aviv, president of Interfor International, a security firm that works with asset managers, told BI on Tuesday that roughly 80% of his firm's clients had "retained additional security for their lobbies and foyers," with some hiking protective services through next week.
"The issue with our society is that we're reactionary and not proactive," Aviv said.
Heightened security comes at a cost
Banks like Goldman Sachs and Citi sought to assuage employees about workplace security on Tuesday.
Goldman Sachs "has robust protocols in place to keep our people safe every day, and is proactively assessing and monitoring the safety of the firm's global campuses to protect our people and facilities around the clock," Goldman said in a memo authorised by Jacqueline Arthur, head of human capital management and corporate and workplace solutions.
"This includes our dedicated team of NYPD officers and security guards at the entrance of and within our buildings, who are trained to carefully manage entry to our offices and respond to any potential incident," Arthur said, adding that Goldman "is constantly assessing" its security protocols.
Citi told New York-based employees on Tuesday that the firm had "increased the security presence and capabilities at our headquarters" within the past year. "This includes working closely with the NYPD," he said. "While we feel confident with the protocols we have in place, we will not hesitate to adjust if necessary," said the memo by Ed Skyler, Citi's head of enterprise services and public affairs.
For companies seeking to boost security, the extra layer of protection won't come cheap. Two security executives in New York City say posting an armed former or off-duty police officer in your lobby will cost building managers $75 to $200 an hour or more. Hiring an armed escort to protect a CEO or other prominent person will cost in the $135 to $200 range per hour.
For now, it's not prohibiting demand. Herman Weisberg said his security company usually hires about 15 armed former military and NYPD officers to protect CEOs and other high-profile individuals in New York and Washington, DC. On Tuesday, that number was up to 30 — and the managing director of SAGE Intelligence thinks it will grow further.
Weisberg, a former NYPD detective, said he is also seeing an increase in requests for "threat assessments," including risks tied to former disgruntled ex-employees.
"One firm," he said, "wants us to work with their customer service department on analyzing current people who are complaining 'outside the norm.'"
He pointed to the back-to-back tragedies of the fatal shooting of UnitedHealthcare's CEO, followed by Monday's attack.
"When this stuff happens more than once, I think anybody with controversial or, at this point, even non-controversial businesses are starting to look at security and take it a little bit more seriously."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNBC
an hour ago
- CNBC
Goldman Sachs' Eric Sheridan talks tech stocks seeing worst trading day in four months
Eric Sheridan, Goldman Sachs, joins 'Closing Bell Overtime' to talk the impact of today's trade news on Big Tech and chip stocks.
Yahoo
an hour ago
- Yahoo
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) ('Protara' or the 'Company'), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees. The Compensation Committee of Protara's Board of Directors approved an aggregate of 14,800 stock option awards and 7,400 RSU awards to two new employees from the Inducement Plan, as inducements material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on August 1, 2025 and have an exercise price of $3.06 per share, Protara's closing trading price on the grant date. Such RSU awards will have a grant date of October 1, 2025. All option awards vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and 1/36th of the underlying shares vesting monthly thereafter over 36 months. All RSU awards vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the grant date. The vesting of all option and RSU awards is subject to the employee's continued service with the company through the applicable vesting dates. About Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit Company Contact: Justine O'Malley Protara 646-817-2836 Source: Protara TherapeuticsSign in to access your portfolio

Miami Herald
an hour ago
- Miami Herald
Ferrari shares dip 12% in biggest decline since 2016 listing
Ferrari shares fell more than 12% on Thursday, the biggest single-day drop since the automaker was first publicly listed on stock exchanges in New York and Milan in 2016, Reuters reports. Yet unlike some automakers, Ferrari is maintaining its financial guidance amid uncertainty over the Trump Administration's tariffs. Citi analysts cited concerns that Ferrari will be able to maintain its profitability momentum in the second half of 2025 amid slowing sales and stagnating transaction prices. In its most recent earnings call, Ferrari said it was more confident in its previous 2025 guidance-which estimates gross earning of just over $3 billion-and reported a 4% increase in net revenue in the second quarter. Ferrari also said in the earnings call that it would remove a 10% price increase on new cars sold in the United States that's been in place since April, following a new trade deal that sets tariffs on cars imported from the European Union at 15%, down from the 27.5% tariff previously imposed by the Trump Administration. According to Reuters, Ferrari CEO Benedetto Vigna said in a media call that almost all cars the automaker sold in the U.S. during the second quarter were shipped before the 27.5% tariff was introduced, so the 10% price increase wasn't applied to them. That's the advantage of being a low-volume automaker with a backlog of orders (Vigna reportedly said Ferrari's current order book extends into 2027). Ferrari is also reportedly still on track to deliver its first all-electric car. Vigna said during the call that he had driven the first electric model, and that it would be shown to analysts in October, according to Reuters. A public debut is expected in spring 2026, with customer deliveries starting later in the year. However, this first EV may be a unique item for a while. Ferrari was reportedly planning to unveil a second EV in late 2026, but has pushed that back to 2028 due to low enthusiasm among its customers. Similar issues have been cited by rivals Lamborghini and Maserati, with the latter completely canceling an electric version of its MC20 supercar due to the lack of takers. Copyright 2025 The Arena Group, Inc. All Rights Reserved.